Engineered immune cells to target SARS-CoV2
AssigneeThe Johns Hopkins University
InventorsChallice Bonifant, Ilias Christodoulou
Life of this patent
Estimating the term…
Abstract
Provided herein are, inter alia, methods, compositions and kits for treating or preventing coronaviruses, e.g., SARS-CoV-2. Also included herein are kits for treating or preventing coronaviruses, e.g., SARS-CoV-2.
Claims17
An engineered immune cell expressing a chimeric antigen receptor (CAR) polypeptide comprising an extracellular banana lectin (BanLec) domain, wherein the CAR polypeptide comprises an amino acid sequence having at least 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity with an amino acid sequence of SEQ ID NO:
- 6, SEQ ID NO:
- 7, SEQ ID NO:9, or SEQ ID NO:11.
An engineered immune cell expressing a chimeric antigen receptor (CAR) polypeptide comprising an extracellular banana lectin (BanLec) domain, wherein the CAR polypeptide is encoded by a sequence having at least 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity with SEQ ID NO:
- 8 or SEQ ID NO:
- 10.
Dependencies are inferred from the claim text.